Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

Recruiting

• Conditions: Cancer

• Registration Number: NCT04567446
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

Multicentric prospective study with collection of biological samples as part of type II research

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-22
• Study First Submitted: 2020-02-10
• Study First Submitted QC: 2020-09-23
• Study First Posted: 2020-09-28
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-11
• Last Update Posted: 2024-06-12
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1100

Inclusion Criteria

• Patient with cancer who will start treatment anticancer (see cohorts).
• Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures.
• Patient affiliated to a social security scheme or beneficiary of a similar scheme.

Exclusion Criteria

• Pregnant or lactating woman
• Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	Up to 2 years	To define metagenomic signatures associated with cancer

Trial Locations

Locations (9)

Gustave Roussy; 🇫🇷 Villejuif, Val De Marne, France

Centre hospitalier du Pays d'Aix; 🇫🇷 Aix-en-Provence, France

Centre Pierre Curie; 🇫🇷 Beuvry, France

Clinique du Flandre; 🇫🇷 Coudekerque-Branche, France

CHRU Lille - Hôpital Calmette; 🇫🇷 Lille, France

Centre Léon Bérard; 🇫🇷 Lyon, France

Hôpital St Louis; 🇫🇷 Paris, France

Hôpital Foch; 🇫🇷 Suresnes, France

Centre hospitalier TOULON - Sainte-Musse; 🇫🇷 Toulon, France